See the DrugPatentWatch profile for Auvelity
Auvelity Approval Status in Europe
As of mid-2024, Auvelity has not yet received approval in Europe [1]. The drug, developed by Axsome Therapeutics, is approved in the United States for the treatment of major depressive disorder (MDD) [1][2].
Why hasn't Auvelity been approved in Europe yet?
The European Medicines Agency (EMA) is the regulatory body responsible for evaluating and approving medicines for use in the European Union [1]. Drug approval processes, particularly for novel treatments, involve rigorous review of clinical trial data to demonstrate safety and efficacy [1]. Axsome Therapeutics has indicated its intention to seek European approval, but specific timelines for the submission and review process for Auvelity in Europe have not been definitively established beyond 2025 [1].
What is Auvelity and how does it work?
Auvelity is an oral medication that combines dextromethorphan and bupropion [2]. Dextromethorphan is a low-affinity uncompetitive antagonist of the NMDA receptor and an agonist of the sigma-1 receptor [2]. Bupropion is an inhibitor of norepinephrine and dopamine reuptake [2]. This dual mechanism of action is believed to modulate glutamatergic and monoaminergic neurotransmission, which are implicated in depression [2].
What are the next steps for Auvelity in Europe?
Axsome Therapeutics must submit a Marketing Authorisation Application (MAA) to the EMA for Auvelity to be considered for approval in Europe [1]. This submission would include comprehensive data from clinical studies conducted for the drug's development [1]. Following submission, the EMA will conduct a scientific evaluation of the data, a process that can take a significant amount of time [1].
When might Auvelity be available in Europe?
While Axsome Therapeutics has stated its commitment to pursuing European approval, a specific launch date or approval timeline for 2025 is not confirmed [1]. The EMA's review process, along with any potential requests for additional information or studies, will determine when a decision might be made [1]. Patients and healthcare providers in Europe will need to await further announcements from Axsome Therapeutics and the EMA regarding the regulatory status [1].
Sources
1. DrugPatentWatch.com
2. Axsome Therapeutics